Rituximab Plus CAMPATH in Patients With Relapsed/Refractory Low-Grade or Follicular, CD20-positive, B-cell NHL

Genzyme

Status and phase

Terminated

Phase 2

Phase 1

Conditions

Non-Hodgkin's Lymphoma

Treatments

Drug: CAMPATH (alemtuzumab)

Study type

Interventional

Funder types

Industry

Identifiers

NCT00077961

CAM.NHL233

Details and patient eligibility

About

The purpose of this study is to determine the optimal dose of subcutaneous CAMPATH when used in combination with rituximab for patients with relapsing or refractory, low-grade or follicular, CD-20-positive, B-Cell non-Hodgkin's Lymphoma. Safety will be the primary objective of phase I, while the primary objective of phase II will be to determine overall response.

Full description

This study is being conducted in 2 parts. Phase I will involve dose escalation of subcutaneous CAMPATH (SQ) given 3 times per week in combination with weekly doses of rituximab (375mg/m2) for a maximum of 8 weeks in order to determine the maximum tolerated dose (MTD). In Phase II patients will be treated with SQ CAMPATH at the MTD plus weekly rituximab (375mg/m2)for a maximum of 8 weeks with primary objective of defining Overall Response (OR) to this combination.

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

For the Phase I portion of the study, patients must have pathologically confirmed diagnosis of low-grade or follicular, CD20-positive, B-cell, non-Hodgkin's lymphoma that has relapsed or is refractory. For the Phase II portion of the study, patients must have a pathologically confirmed diagnosis of low-grade or follicular, CD20-positive, B-cell, non-Hodgkin's lymphoma (Follicular, predominantly small cleaved or follicular, mixed small cleaved and large cell, International Working Formulation classification B or C or REAL classification follicular center grade 1,2) that has relapsed or is refractory.
Previously treated with at least one anti-cancer regimen for NHL
Measurable disease (lesions that can be accurately measured in 2 dimensions by CT scan with a greatest transverse diameter of >/= to 2cm or palpable lesions with both diameters of 2cm or more)
Life expectancy of at least 12 weeks
WHO performance status or 0 or 1
Adequate marrow and organ function (as defined in the protocol)
Completed major surgery, radiotherapy, chemotherapy, immunotherapy or biotherapy/targeted therapies at least 4 weeks prior to study entry (6 weeks if treated with a nitrosourea or mitomycin). Patients must have recovered from all prior treatment toxicity to Grade 1 or less, exclusive of alopecia.

Exclusion criteria

Prior combination therapy with rituximab and CAMPATH; prior therapy with either agent alone is permitted
A history of a T-cell lymphoma
Known AIDS-related HIV-positive lymphoma
For the Phase II portion of the study (once MTD has been determined), bulky disease, ie, any single mass >10cm or circulating malignant cells of 25,000/uL or more
Prior autologous bone marrow or stem cell transplant within 6 months of study entry
Prior allogeneic bone marrow transplant or organ transplant
Prior radiotherapy to the only site of measurable disease
Medical condition requiring chronic use of oral, high-dose corticosteroids
Use of investigational agents within 30 days of study enrollment
Past history of anaphylaxis following exposure to humanized monoclonal antibodies
Known, active, infection, including HIV positive
Diagnosis of another malignancy within the previous five (5) years, unless the probability of recurrence of the prior malignancy is < 5%. Patients with curatively treated early stage squamous cell carcinoma of the skin, basal cell carcinoma of the skin, cervical intraepithelial neoplasia (CIN), and patients with a history of malignant tumor in the past that have been disease-free for at least 5 years
Active central nervous system (CNS) involvement with lymphoma
Pregnant or nursing women
Any significant concurrent disease or illness that would, in the opinion of the investigator, compromise patient safety or compliance, or interfere with the interpretation of study results
Active hepatitis or a history of prior viral hepatitis B or C, or positive hepatitis B serologies without prior immunization